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Abstract
While the chemotherapeutic effect of curcumin, one of three major curcuminoids derived from
turmeric, has been reported, largely unexplored are the effects of complex turmeric extracts more
analogous to traditional medicinal preparations, as well as the relative importance of the three
curcuminoids and their metabolites as anti-cancer agents. These studies document the
pharmacodynamic effects of chemically-complex turmeric extracts relative to curcuminoids on
human breast cancer cell growth and tumor cell secretion of parathyroid hormone-related protein
(PTHrP), an important driver of cancer bone metastasis. Finally, relative effects of structurally-
related metabolites of curcuminoids were assessed on the same endpoints. We report that 3
curcuminoid-containing turmeric extracts differing with respect to the inclusion of additional
naturally occurring chemicals (essential oils and/or polar compounds) were equipotent in
inhibiting human breast cancer MDA-MB-231 cell growth (IC50=10–16μg/mL) and secretion of
osteolytic PTHrP (IC50=2–3μg/mL) when concentrations were normalized to curcuminoid
content. Moreover, these effects were curcuminoid-specific, as botanically-related gingerol
containing extracts had no effect. While curcumin and bis-demethoxycurcumin were equipotent to
each other and to the naturally occurring curcuminoid mixture (IC50=58 μM), demethoxycurcumin
was without effect on cell growth. However, each of the individual curcuminoids inhibited PTHrP
secretion (IC50=22–31μM) to the same degree as the curcuminoid mixture (IC50=16 μM).
Degradative curcuminoid metabolites (vanillin and ferulic acid) did not inhibit cell growth or
PTHrP, while reduced metabolites (tetrahydrocurcuminoids) had inhibitory effects on cell growth
and PTHrP secretion but only at concentrations ≥10-fold higher than the curcuminoids. These
studies emphasize the structural and biological importance of curcuminoids in the anti-breast
cancer effects of turmeric and contradict recent assertions that certain of the curcuminoid
metabolites studied here mediate these anti-cancer effects.
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Breast cancer is the most common cancer among women worldwide [1]. However, the
incidence of breast cancer in India is among the lowest in the world [2]. While the reasons
for this are likely multifactorial, it is interesting to note that India also has the highest
worldwide consumption of turmeric, a primary source of dietary curcumin. Curcumin has
been well described in numerous in vitro studies to inhibit the growth of breast cancer cells
[3]. Also, a separate beneficial effect of turmeric-derived curcuminoids in breast cancer,
independent of effects on cell growth, has recently been identified in our laboratories; in an
experimental model of breast cancer bone metastases, curcuminoids inhibited the
development of osteolyic bone lesions, which occur in a majority of women with advanced
metastatic disease [4], by inhibiting breast cancer cell secretion of osteolytic factors (e.g.,
parathyroid hormone-related hormone [PTHrP]) [5].
Turmeric has a rich history of medicinal use in Ayurveda, a Hindu system of traditional
medicine native to India [6]. While chemically complex turmeric preparations are used
ethnobotanically, purified curcumin(oid)-only products are the most common form of
turmeric studied medicinally or sold as dietary supplements in western countries [7].
However, medicinal and/or health promoting effects of curcumin or turmeric’s naturally
occurring mixture of curcuminoids (curcumin, demethoxycurcumin, and bis-
demethoxycurcumin) have been called into question because serum levels are low when
curcumin(oids) are administered orally in purified forms [8]. To resolve this apparent
discrepancy between turmeric bioactivity and curcuminoid bioavailability, it has been
proposed that curcuminoid metabolites, including degradative or reduced products, may be
the bioactive moieties responsible for mediating curcumin(oid) effects [9]. Alternatively, or
additionally, it is also possible that chemically complex (vs. curcuminoid-only) turmeric
products may have differential pharmacodynamic and/or pharmacokinetic profiles that
would explain/support their ethnobotanical use despite the low bioavailability documented
for purified nontraditional, curcuminoid-only products. For example, emerging evidence
from our laboratories and others have demonstrated independent bioactivity of another class
of turmeric secondary metabolites, the essential oils [10], as well as enhanced oral
curcuminoid bioavailability when administered in combination with the oils [11]. Thus,
examination of possible roles of curcuminoid metabolites and/or curcuminoid interactions
with other turmeric-derived compounds in mediating turmeric bioactivity is a viable
research question with particular relevance to modern vs. traditional uses of turmeric for the
purpose of limiting breast cancer occurrence or progression.
Studies reported here were undertaken to investigate two lines of inquiry related to turmeric
use in breast cancer, examining (1) the relative pharmacodynamic effects of chemically
complex vs. curcuminoid-only turmeric extracts on breast cancer cell growth and the
secretion of osteolytic factors (PTHrP) important for breast cancer bone metastases
progression, and (2) the relative pharmacodynamic effects of curcuminoids vs. their
metabolites or other structurally- or botanically-related compounds on these same endpoints.
These systematic studies were undertaken using human MDA-MB-231 cells, a frequently
studied human breast cancer cell line that is triple negative for the estrogen, progesterone
and EGF type 2 (HER2) receptors [12], thus representing an aggressive breast cancer
phenotype [13], in order to query the importance of curcuminoids in mediating turmeric’s
protective effects in breast cancer, as well as to assess structural features of the
curcuminoids required for bioactivity in this common female malignancy.
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Extract isolation and chemical analyses
Dried powdered rhizomes of turmeric (Curcuma longa L.) and ginger (Zingiber officinale
Roscoe) were purchased from San Francisco Herb and Natural Food (San Francisco, CA)
and experimental extracts were prepared and analyzed by HPLC for phenolic content as
previously described [7,14,15]. Briefly, dried powdered turmeric rhizome was extracted
with 1) methanol to prepare a crude turmeric extract containing curcuminoids, curcuminoid-
related compounds, polar compounds, and essential oils (“crude turmeric,” 9.6% yield, 34%
curcuminoids); 2) hexane to prepare an essential oil-only fraction (“turmeric essential oils”,
3.7% yield) or 3) the hexane marc was extracted with methanol to prepare an essential oil-
free fraction containing curcuminoids, curcuminoid-related compounds and polar
compounds (“curcuminoid fraction”, 3% yield; 52% curcuminoids, 28% polar compounds).
A commercial curcuminoid-enriched essential oil-free product analogous in composition to
currently available turmeric dietary supplements [16] was purchased from Fisher Scientific
(#218580100, Lot A019754401; “curcuminoids” [76.9% curcumin, 17.6%
demethoxycurcumin, 5.5% bisdemethoxycurcumin]). A crude ginger extract containing
gingerols, gingerol-related compounds, polar compounds and essential oils (“crude ginger,”
6.4% yield) was prepared by extracting the dried ground ginger rhizome powder with
dichloromethane (DCM). The resultant DCM extract was subjected to silica gel
chromatography to yield 3 fractions: a fraction containing gingerols and their derivatives
(“gingerol fraction,” 50% yield), a fraction containing only the essential oils (“ginger
essential oils,” 22% yield) and a fraction containing polar compounds (30% yield, not tested
here). Content of major phenolic compounds in extracts derived from dried ground rhizomes
of turmeric (curcumin, demethoxycurcumin, and bis-demethoxycurcumin) and ginger (6-,
8-, and 10-gingerol) were determined by HPLC analysis as previously described [7,14].
Curcumin (#03926), demethoxycurcumin (#04230), bis-demethoxycurcumin (#04231), 6-
gingerol (#07164), ferulic acid (#06005), and vanillin (#22305) were purchased from
ChromaDex (≥ 92% pure). Tetrahydrocurcuminoids, manufactured by reduction of the
naturally occurring mixture of curcuminoids present in turmeric (SBX0069; ≥96% pure),
were a kind gift from Sabinsa Corporation. Stock solutions of experimental and commercial
products were prepared using DMSO (100 – 300 mg/mL) and stored at 4 °C. Stability of
curcuminoid containing stock solutions and/or extracts was verified at 12-month intervals by
HPLC.
Cell cultures
Human breast cancer MDA-MB-231 cells (a kind gift from Dr. Theresa Guise, Indiana
University), one of the most frequently studied estrogen-receptor negative human breast
cancer cell lines, were used for these studies. To authenticate these cells, genomic DNA was
genotyped for 9 Autosomal STR loci and Amelogenin (X/Y) using Promega Stem Elite PCR
kit as per the manufacturer’s recommended cycling conditions with separation of PCR
products by capillary electrophoresis on an AB 3730 DNA Analyzer. Positive and negative
control samples and manufacturer’s allelic ladder were used to ensure allelic call
calibrations. Electropherograms were analyzed and allelic values assigned using Soft
Genetics, Gene Marker software version 1.85. Alleles were matched to STR Profile recorded
with ATCC thus confirming the identity of the human breast cancer cell line MDA-MB-231
used here. For analysis of botanical effects on cell viability, cytotoxicity or PTHrP secretion,
subconfluent MDA-MB-231 cells were plated at 5 × 104 cells/cm2 and incubated overnight
in fresh DMEM medium containing 10% fetal bovine serum and antibiotics at 37°C and 5%
CO2 in a humidified atmosphere. Cells were pre-incubated with indicated botanical
treatments for 4 h and media was then refreshed with the addition of recombinant human
TGF-β1 (5 ng/mL; R&D Systems) for 24 h to stimulate PTHrP secretion. Parathyroid
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hormone-related protein (PTHrP) was measured in conditioned media after 24 h by
commercial radioimmunoassay (Diagnostic Systems Laboratories). Effects on cell viability
and cytotoxicity were measured by assay of cell number assessed by mitochondrial
reduction of MTT (ATCC) and conditioned media content of lactate dehydrogenase (LDH;
Promega), respectively, as per manufacturer’s protocol. Treatment concentrations of phenol-
containing turmeric and ginger extracts were normalized to, and expressed as, total content
(μg/mL) of curcuminoids (curcumin, demethoxycurcumin, and bisdemethoxycurcumin) or
gingerols (6-, 8- and 10-gingerol), respectively, while pure essential oils are expressed by
weight (μg oil/mL).
Statistical analyses
Data are expressed as mean ± SEM. Half maximal inhibitory concentrations (IC50) were
obtained by analyzing concentration-response data using a four-parameter logistic equation,
assigning a maximum value of 100% and a minimum value of > 0% (Prism 4.0 software,
GraphPad, San Diego, CA). Statistically significant differences between IC50 values were
determined by F test with p < 0.05 (Prism 4.0 software, GraphPad). Where indicated,
differences between means were determined by one-way ANOVA with Student Newman
Keuls post hoc test using Instat 3.0 software (Graphpad).
Results
Effects of multicomponent turmeric extracts on human breast cancer cell viability and
PTHrP secretion
Chemically complex (crude extract or essential oil-free curcuminoid fraction) vs. purified
curcuminoid-only turmeric extracts, when normalized to curcuminoid content, were
statistically equipotent in decreasing human breast cancer MDA-MB-231 cell viability, with
IC50 values of 10–16 μg curcuminoids/mL (Figure 1A). Isolated turmeric essential oils also
decreased cell viability, but were less potent (Figure 1A). Chemically complex vs.
curcuminoid-only extracts were equipotent inhibitors of osteolytic PTHrP secretion when
normalized to curcuminoid content (IC50 = 2–3 μg/mL) (Figure 1B). Isolated essential oils
actually increased PTHrP secretion, a potentially adverse biological effect (Figure 1B).
However, the essential oil content of the crude turmeric extract did not appear to mitigate
the beneficial PTHrP inhibitory effects of the curcuminoids since crude extract potency was
statistically no different from that of curcuminoid extracts lacking essential oils (essential-oil
free curcuminoid fraction or purified curcuminoids) (Figure 1B). To examine this further,
PTHrP inhibitory effects of purified curcuminoids vs. turmeric essential oils were tested
alone and in combination (Figure 1C). At the doses tested (5 μg curcuminoids or oil/mL),
the PTHrP inhibitory effect of the curcuminoids was not blocked by addition of the oils;
indeed, while similar in magnitude to the effects of curcuminoids, PTHrP inhibition by
combined treatment was actually statistically greater than that of the curcuminoids alone
(Figure 1C). Curcuminoid inhibition of cell viability, as determined by MTT assay, occurred
in parallel with cytotoxicity, as determined by assay of LDH content of conditioned media
(Figure 1D).
Effects of turmeric’s phenolic and essential oil components on breast cancer cell viability
and secretion of osteolytic PTHrP were compared to those of crude and similarly
fractionated extracts prepared from rhizomes of ginger, a related plant of the Zingiberaceae
family also known for its medicinal phenolics (gingerols) and essential oils [15]. The crude
ginger extract (normalized to gingerol content) containing phenols, essential oils and polar
compounds, as well as the essential oils alone, decreased cell viability with potencies greater
than that of the crude turmeric extract (IC50 = 4 μg/mL) (Figure 2A). However, in contrast
to the equipotent growth inhibitory effect of all curcuminoid-containing turmeric extracts,
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ginger’s phenolic fraction had no effect on breast cancer cell viability when administered in
isolation (Figure 2A). While turmeric’s curcuminoids almost completely inhibited PTHrP
secretion at doses as low as 10 μg/mL (Figure 1B), similar doses of ginger-derived phenolics
were without effect (Figure 2B). Ginger essential oils, analogous to turmeric essential oils,
increased PTHrP secretion (Figure 2B; p < 0.001 for 30 μg/mL).
Effects of curcumin, demethoxycurcumin and bis-demethoxycurcumin vs. naturally
occurring mixture of curcuminoids on breast cancer cell viability and secretion of
osteolytic PTHrP
Because beneficial effects of chemically complex turmeric extracts on human MDA-
MB-231 breast cancer cells, with respect to both cell viability and the secretion of osteolytic
factors, appeared to be associated with curcuminoid content, the relative potency of purified
curcumin, demethoxycurcumin or bis-demethoxycurcumin vs. the naturally occurring
curcuminoid mixture on breast cancer cell viability and secretion of osteolytic PTHrP were
determined. Curcumin and bis-demethoxycurcumin, typically the most and least abundant of
turmeric’s curcuminoids, respectively [7], were statistically equipotent to the naturally
occurring curcuminoid mixture in decreasing cell viability, while demethoxycurcumin was
without any statistically significant effect (Figure 3A). In contrast to the differential effects
of curcumin and bis-demethoxycurcumin vs. demethoxycurcumin on breast cancer cell
viability, each of the individual curcuminoids inhibited PTHrP secretion (IC50 = 22–31 μM)
and was statistically equipotent to the naturally occurring mixture of curcuminoids (Figure
3B).
Effects of curcuminoid metabolites and related compounds on breast cancer cell viability
and secretion of osteolytic PTHrP
The importance of structural elements of the curcuminoids, in addition to their differing
phenolic methoxy-group substitutions, to their bioactivity in human breast cancer cells were
further explored by comparison of curcuminoids with structurally related natural products
(e.g., 6-gingerol), including reduced (tetrahydrocurcuminoids) and degradative (vanillin and
ferulic acid) metabolites of the curcuminoids that have been reported to be produced in vitro
and/or in vivo (Figure 4) [8,12,17–22]. None of the structurally related compounds altered
breast cancer cell viability except for a minor inhibitory effect of the
tetrahydrocurcuminoids at the highest concentration tested (300 μM) (Figure 5A); in
contrast, this same concentration of curcuminoids (300 μM) caused the death of almost 80%
of the breast cancer cells (Figure 5A and Figure 1D). With respect to inhibition of osteolytic
PTHrP secretion, the degradative metabolites of the curcuminoids, vanillin and ferulic acid,
were also without effect (Figure 5B); indeed, high dose ferulic acid actually stimulated
PTHrP secretion, a potentially adverse biological effect. Tetrahydrocurcuminoids, a
reductive metabolite of the curcuminoids, did significantly inhibit PTHrP secretion, but with
a 10-fold lower potency (Figure 5B). Similarly, 6-gingerol, while inhibiting PTHrP
secretion, was 10-fold less potent than the curcuminoids (IC50 = 133 μM vs. 16 μM);
indeed, while a curcuminoid concentration of 100 μM completely inhibited PTHrP
secretion, a similar dose of 6-gingerol was without any statistically significant effect (Figure
5B).
Discussion
A large body of literature has documented beneficial effects of curcumin, one of three major
curcuminoids derived from the medicinal turmeric rhizome, on cancer cell growth in vitro,
including breast cancer [3,23]. Largely unexplored, however, have been the effects and
bioactive components of chemically complex turmeric extracts that more closely model
human exposure associated with culinary or traditional medicinal use of turmeric. Results
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from the studies presented here clearly demonstrate the unique ability of turmeric-derived
phenolic compounds to inhibit breast cancer cell growth and the secretion of important
osteolytic factors that drive breast cancer bone metastases in advanced disease [4]. These
protective effects of turmeric’s phenolic compounds were specific to the curcuminoids as,
for example, botanically and chemically related phenols isolated from ginger were without
effect within a similar concentration range. The importance of studying the bioactivity of
clinically-relevant, chemically-complex botanical extracts is underscored by the discovery
that the secondary oils of turmeric (and of ginger) could have adverse effects in breast
cancer, as the essential oils actually enhanced breast cancer cell secretion of osteolytic
factors. Fortunately, however, in the case of chemically complex turmeric use, when
turmeric’s essential oils were combined with the curcuminoids, the beneficial effect of the
phenolic compounds was retained. Also of interest vis à vis the study of chemically complex
botanicals, while the phenolics in turmeric were the most potent bioactive moieties with
respect to breast cancer growth inhibition, the most potent secondary metabolites in ginger
extracts were, instead, the essential oils.
The relative potency of the curcuminoids when used in combination or isolation to treat
human breast cancer cells differed for each of the two investigated endpoints—cell growth
vs. secretion of osteolytic PTHrP. Growth inhibitory effects of the curcuminoids in breast
cancer have previously been attributed to their targeting of cell cycle and/or apoptotic
cellular pathways [24–26]; our demonstration of equipotent effects of the curcuminoids on
cell viability, as measured by MTT assay, and cytotoxicity, as measured by release of LDH
into the media, is consistent with a pro-apoptotic, rather than anti-proliferative effect.
Interestingly, demethoxycurcumin was less potent than the two other naturally occurring
curcuminoids in blocking breast cancer cell viability. In contrast, all three curcuminoids
were equipotent in blocking PTHrP secretion, having IC50 values that were ≥ 5-fold lower
than those required to induce cell death. It has been reported that bisdemethoxycurcumin is
the most stable of the curcuminoids [27] and that the stability of curcumin is enhanced in the
presence of demethoxycurcumin [28]. However, because bisdemethoxycurcumin, curcumin
and the naturally occurring mixture of curcuminoids were equipotent in inhibiting cell
viability and blocking PTHrP secretion, this suggests that any potential differences in their
relative stabilities did not alter bioactivity. Similarly, the lack of effect of
demethoxycurcumin on cell viability was not likely due to a decrease in stability when
administered in isolation since this compound remained equipotent to the other
curcuminoids when blocking PTHrP secretion.
While not investigated here, because our previous studies have identified Smad-mediated
transforming growth factor (TGF)-β signaling as the cellular pathway targeted by
curcuminoids when inhibiting PTHrP secretion in human breast cancer MDA-MB-231 cells
[5], the demonstration in these studies of equipotent effects of each of the curcuminoids in
blocking PTHrP secretion suggests that each of these three compounds may have similar
efficacy in blocking Smad-mediated TGF-β signaling. TGF-β signaling induces PTHrP
secretion independent of any stimulatory effects on cell growth rate; indeed, prolonged
treatment with TGF-β at high concentrations decreases MDA-MB-231 cell number (29).
Therefore, the inhibitory effects of curcuminoids on cell viability cannot be attributed to
blockade of Smad-mediated TGF-β, but rather is likely due to targeting of a second, non-
TGF-β pathway regulating cell death. The less potent effects of the curcuminoids in
blocking cell viability (via PTHrP secretion) as well as the differential effects of the
individual curcuminoids in limiting cancer cell viability (vs. their equipotent effects in
blocking PTHrP secretion) suggests that: 1) the structural elements of the curcuminoids
required for their bioactivity vary with the biological target, and that 2) curcuminoids have
multiple biological targets within a given cell [23]. Evidence from other studies supports this
conclusion, as, for example, curcumin has been reported to be the least effective of the
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curcuminoids in blocking MMP-3 secretion from the same cell line used here [30]. With
regard to anti-oxidative properties, curcumin has typically been the most potent of the three
curcuminoids when tested head-to-head [22,31,32], a phenomenon that has been attributed
to the functional importance of its two methoxy groups (compared to one for
demethoxycurcumin and none for bis-demethoxycurcumin). Cyclooxygenase-2 (COX-2)
inhibition, another much studied function of curcumin, has also been attributed to the 2-
methoxy phenolic structure [33]. Consistent with our studies, however, many anti-cancer
studies have described demethoxycurcumin or bis-demethoxycurcumin as equally and
sometimes more potent than curcumin [27,34,35], indicating that the methoxy moieties are
not conferring bioactivity in these cases. From a practical standpoint, given that a majority
of turmeric dietary supplements available for clinical use or research are comprised of the
naturally occurring mixture of curcuminoids [7], our demonstration of equal or greater
potency of the mixture vs. single compounds justifies continued testing of curcuminoids as a
mixture for their chemotherapeutic potential in breast cancer.
Given the low circulating levels of curcuminoids in vivo, as well as the diverse documented
effects of curcuminoids in biological systems, a potential role for known curcuminoid
metabolites in mediating their bioactivity has been postulated [9,36]. Among these
discussions, a postulate has been put forth that ferulic acid and vanillin, both degradative
products of the curcuminoids, are responsible for the biological effects of the curcuminoids,
including their anti-tumor effects [9]. While it may be possible that other metabolites of
curcuminoids are bioactive, evidence presented here clearly demonstrates that the
degradative metabolites, ferulic acid and vanillin, are not able to inhibit breast cancer cell
growth or the secretion of osteolytic PTHrP. Indeed, ferulic acid at high doses acted in
opposite fashion as compared to curcuminoids and stimulated, rather than suppressed, breast
cancer cell PTHrP secretion. Consistent with our findings, vanillin and ferulic acid, even at
high concentrations, have been demonstrated by others to have minimal effect on other
known curcuminoid targets, including cyclooxygenase enzyme and NF-κB [37–40],
suggesting that these metabolites are not mediating curcuminoid biological effects. What is
more, vanillin and ferulic acid have not been identified as abundant degradation products of
curcuminoids in vitro [19,41,42] and are not reported to be major metabolites in vivo
[21,22], casting further doubt on the postulate that vanillin and ferulic acid are responsible
for the bioactivity of curcuminoids. Thus, results reported here using MDA-MB-231 cells as
a breast cancer model system suggest that turmeric-derived curcuminoids possess potent
anti-cancer activity, while certain other structurally related compounds, such as ferulic acid,
a major phenolic compound that is also found in the cell walls of important dietary
monocotyledons (e.g., rice, wheat, maize) [43,44], do not.
The absence of an inhibitory effect of vanillin and ferulic acid, both of which lack the
curcuminoids’ heptadienone chain, on MDA-MB-231 cell viability and PTHrP secretion
suggest that this structural element may be important for curcuminoid bioactivity in breast
cancer. Consistent with this hypothesis, loss of this structural element when curcuminoids
are reduced to form tetrahydrocurcuminoids, a biotransformation that occurs in vitro and in
vivo [21,22], was associated with a 10-fold decrease in potency with respect to inhibition of
PTHrP secretion and a > 10- fold loss of potency with respect to inhibitory effects on cell
growth. Tetrahydrocurcuminoids have similarly been demonstrated by others to be less
potent than the curcuminoids as an anti-tumor agents [45–47], while retaining anti-oxidative
properties relative to their parent compounds [32,47,48], likely due to the common presence
of hydroxyl moieties [31,46]. While the exact functional significance of the curcuminoid
heptadienone chain in breast cancer was unstudied here, previous studies have reported anti-
cancer bioactivity of curcumin analogues that retain this Michael acceptor dienone moiety
[49]. The heptadienone chain has recently been reported by Schneider et al [41,42] to be a
required element for the autooxidation of curcumin, an alternative metabolic pathway not
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evaluated here [41]. Thus future studies are needed to assess a potential role of oxidative
metabolites in mediating the anticancer effects of the curcuminoids reported here.
Interestingly, while gingerols present in complex ginger extracts were without effect at
clinically relevant concentrations in targeting breast cancer cells, higher doses of purified 6-
gingerol were equipotent to the tetrahydrocurcuminoids in blocking PTHrP secretion (and
similarly ineffective in inhibiting cell growth). This suggests that the complete lack of
activity of the mono-phenolic degradative metabolites of the curcuminoids (ferulic acid and
vanillin) cannot simply be attributed to the absence of the second phenolic group. Clearly,
however, these findings again point to turmeric-derived curcuminoids as the most potent of
a series of botanically-and structurally-related naturally-occurring phenolics with respect to
anti-breast cancer activity.
Conclusion
Turmeric has a rich history of medicinal use. Our findings demonstrated that polyphenolic
curcuminoids were responsible for the anti-breast cancer activity of chemically complex
turmeric extracts, and that a naturally-occurring mixture of the three curcuminoids was as
potent as the individual curcuminoids in inhibiting cancer cell growth and expression of the
osteolytic factor PTHrP. We also demonstrated that curcuminoid metabolites, vanillin,
ferulic acid and tetrahydrocurcuminoids were not potent inhibitors of breast cancer cell
growth or secretion of osteolytic PTHrP, despite recent assertions that they are responsible
for the bioactivity of curcuminoids. These studies emphasize the structural and biological
importance of curcuminoids in the anti-cancer effect of turmeric.
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Effect of chemically complex turmeric extracts and fractions on human breast cancer MDA-
MB-231 cell viability, cytotoxicity and secretion of osteolytic PTHrP. As indicated in the
methods, MDA-MB-231 cells (n = 4–8/group) were treated with botanicals for 4 hours prior
to stimulation with TGFβ for 24 hours, after which time (A) cell viability was assessed by
MTT assay and (B) PTHrP secretion was determined by radioimmunometric assay of
conditioned media. Concentrations of all curcuminoid-containing extracts were normalized
to curcuminoid content (†). Half maximal inhibitory concentrations (IC50) were obtained
using a four-parameter logistic equation with statistically significant differences between
IC50 values determined by F test with p < 0.05. (C) Effects of purified curcuminoids (5 μg/
ml) and turmeric essential oils (5 μg/ml) alone or in combination on PTHrP secretion (n = 4/
group), and (D) effects of purified curcuminoids on cell viability (MTT assay) vs.
cytotoxicity (LDH content of media) (n = 4/group) were compared with statistically
significant effects determined by ANOVA with post-hoc testing. *p < 0.05 vs. control. ***p
< 0.001 vs control.
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Effect of chemically complex ginger extracts and fractions on human breast cancer MDA-
MB-231 cell viability and secretion of osteolytic PTHrP. As indicated in the methods,
MDA-MB-231 cells (n = 4–8/group) were treated with botanicals for 4 hours prior to
stimulation with TGFβ for 24 hours, after which time (A) cell viability was assessed by
MTT assay and (B) PTHrP secretion was determined by radioimmunometric assay of
conditioned media. Concentrations of all gingerol-containing extracts were normalized to
gingerol content (†). Half maximal inhibitory concentrations (IC50) were obtained using a
four-parameter logistic equation with statistically significant differences between IC50
values determined by F test with p < 0.05.
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Comparative effects of curcuminoids, curcumin, demethoxycurcumin and bis-
demethoxycurcumin on human breast cancer MDA-MB-231 cell viability and secretion of
osteolytic PTHrP. MDA-MB-231 cells (n = 8–20/group) were treated with botanicals for 4
hours prior to stimulation with TGFβ for 24 hours, after which time (A) cell viability was
assessed by MTT assay and (B) PTHrP secretion was determined by radioimmunometric
assay of conditioned media. Half maximal inhibitory concentrations (IC50) were obtained
using a four-parameter logistic equation with statistically significant differences between
IC50 values determined by F test with p < 0.05. Statistically significant effects of each
botanical (vs. controls or each other) were also determined by ANOVA with post hoc
testing. * p < 0.001 (vs. control) for curcumin or curcuminoids. ** p < 0.001 (vs. control)
for bis-demethoxycurcumin.
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Chemical structures of curcumin and related compounds tested.
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Comparative effects of curcuminoids, tetrahydrocurcuminoids, ferulic acid, vanillin, and 6-
gingerol on human breast cancer MDA-MB-231 cell viability and secretion of osteolytic
PTHrP. MDA-MB-231 cells (n = 8–16 per group) were treated with botanicals for 4 hours
prior to stimulation with TGFβ for 24 hours, after which time (A) cell viability was assessed
by MTT assay and (B) PTHrP secretion was determined by radioimmunometric assay of
conditioned media. Half maximal inhibitory concentrations (IC50) were obtained using a
four-parameter logistic equation with statistically significant differences between IC50
values determined by F test with p < 0.05. For each compound, statistically significant
effects (vs. control) were determined by ANOVA with post-hoc testing. *p < 0.05. ** p <
0.01. ***p < 0.001.
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